Format

Send to

Choose Destination
Parkinsonism Relat Disord. 2018 Apr;49:4-8. doi: 10.1016/j.parkreldis.2018.01.018. Epub 2018 Jan 31.

Evolution of cerebrospinal fluid total α-synuclein in Parkinson's disease.

Author information

1
The Norwegian Centre for Movement Disorders, Stavanger University Hospital, PO Box 8100, 4068, Stavanger, Norway.
2
Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital at Mölndal, University of Gothenburg, 43180, Mölndal, Sweden.
3
Section of Biostatistics, Department of Research, Stavanger University Hospital, PO Box 8100, 4068, Stavanger, Norway.
4
Department of Neurology, Haukeland University Hospital, PO Box 1400, 5021, Bergen, Norway; Institute for Clinical Medicine, University of Bergen, PO Box 1400, 5021, Bergen, Norway.
5
Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital at Mölndal, University of Gothenburg, 43180, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, 43180, Mölndal, Sweden.
6
Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital at Mölndal, University of Gothenburg, 43180, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, 43180, Mölndal, Sweden; Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, Gower Street, WC1E 6BT, London, UK; UK Dementia Research Institute, Box 16, National Hospital for Neurology and Neurosurgery, Queen Square, WC1N 3BG, London, UK.
7
The Norwegian Centre for Movement Disorders, Stavanger University Hospital, PO Box 8100, 4068, Stavanger, Norway; Department of Neurology, Stavanger University Hospital, PO Box 8100, 4068, Stavanger, Norway.
8
The Norwegian Centre for Movement Disorders, Stavanger University Hospital, PO Box 8100, 4068, Stavanger, Norway; Department of Neurology, Stavanger University Hospital, PO Box 8100, 4068, Stavanger, Norway; Department of Mathematics and Natural Sciences, University of Stavanger, Stavanger, Norway.
9
The Norwegian Centre for Movement Disorders, Stavanger University Hospital, PO Box 8100, 4068, Stavanger, Norway. Electronic address: johannes.lange@sus.no.

Abstract

INTRODUCTION:

Cerebrospinal fluid (CSF) total α-synuclein is considered a potential biomarker for Parkinson's disease (PD), but little is known about the evolution of this marker during the course of the disease. Our objective was to investigate whether CSF total α-synuclein concentrations change over time and are associated with motor and cognitive function in PD.

METHODS:

CSF total α-synuclein concentrations were quantified in 56 longitudinally followed PD patients, 27 of whom provided CSF repeatedly 2 and/or 4 years later. Another 18 subjects were included as controls. The samples were analyzed using two independent, validated ELISA methods: our recently developed and validated in-house ELISA and a commercial kit from BioLegend.

RESULTS:

CSF total α-synuclein levels did not distinguish PD patients from controls, displayed no substantial changes during a period of up to 4 years, and did not predict subsequent motor or cognitive decline. These findings were consistent for both analytical methods.

CONCLUSION:

Our findings do not support the clinical utility of total α-synuclein as a single diagnostic or prognostic biomarker in PD.

KEYWORDS:

Biomarker; Cerebrospinal fluid; Longitudinal measurements; Parkinson's disease; α-synuclein

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center